Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvantBram Van Den Eeckhout, Sarah Gerlo|npj Vaccines|2020Cited by 27
In-depth Analysis of the HIV Reservoir Confirms Effectiveness and Safety of Dolutegravir/Lamivudine in a Phase 4 Randomized Controlled Switch Trial (RUMBA)Marie‐Angélique De Scheerder, Linos Vandekerckhove, Mareva Delporte et al.|The Journal of Infectious Diseases|2024Cited by 8
Rethinking IL-1 Antagonism in Respiratory Viral Infections: A Role for IL-1 Signaling in the Development of Antiviral T Cell ImmunityBram Van Den Eeckhout, Sarah Gerlo|International Journal of Molecular Sciences|2023Cited by 5